Previous close | 4.0700 |
Open | 3.8628 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's range | 3.8446 - 4.4301 |
52-week range | 1.7160 - 9.0000 |
Volume | |
Avg. volume | 19,185 |
Market cap | 7.335M |
Beta (5Y monthly) | 1.53 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
- 2023 Revenue Increased 6% Year-Over-Year, with a 39% Increase in Full-Year Cannabinoid Revenue - - Drove Year-over-Year General and Administrative Expense Reductions of 26% in Q4 2023 and 24% for the Full Year - - Completed Sale of Non-Cannabinoid Herbal Brands Business on March 21, 2024 for $8.02 Million, Including $7.02 Million in Cash Paid at Closing - TOCANCIPÁ, Colombia, April 01, 2024 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW) (“Clever Leaves” or the “Company”)
TOCANCIPÁ, Colombia, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW) (“Clever Leaves” or the “Company”), a global medicinal cannabis company, announced today that through its partnership with award-winning Dutch seed bank, Paradise Seeds (“Paradise”), to develop and register high performance cannabis cultivars in Colombia, Clever Leaves will have exclusive license to cultivate some of these genetics, while Paradise will make other cultivars available to third
Multinational operator has been granted Australian GMP certification by the TGA for the manufacturing of cannabis products. Clever Leaves is the first and only medicinal cannabis company globally that has GMP certifications from the European Union, Colombia, Brazil and Australia. TOCANCIPÁ, Colombia, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW), a global medicinal cannabis company, announced today that it has been granted Australian GMP certification for it